恶性肿瘤合并心房颤动患者射频消融可行性的单中心回顾性研究
本研究为单中心回顾性研究,纳入90例首次行房颤射频消融患者,比较合并恶性肿瘤组(30例)与非肿瘤组(60例)的房颤复发率。随访(328.7±110.2)天,两组复发率分别为20.0%和28.3%,差异无统计学意义;多因素Cox回归显示恶性肿瘤并非房颤复发的独立预测因素(HR=0.508,95%CI 0.192~1.342,P=0.172)。结论提示合并恶性肿瘤对射频消融术后房颤复发无显著影响,射频消融可作为此类患者可行的节律控制策略。
要点
- 合并恶性肿瘤的房颤患者射频消融术后复发率与无肿瘤患者相似。
- 恶性肿瘤并非射频消融术后房颤复发的独立预测因素。
- 对合并恶性肿瘤的房颤患者,射频消融可作为可行的节律控制策略。
核心结论
- 罹患恶性肿瘤对射频消融术后房颤复发无影响,射频消融治疗可视为合并房颤的恶性肿瘤患者可行的心脏节律控制策略。
研究设计与样本
- 单中心回顾性研究,纳入2008年5月30日至2018年9月30日于大连医科大学附属第一医院首次行射频消融治疗的房颤患者,肿瘤组30例,非肿瘤对照组60例,共90例。
主要发现
- 随访(328.7±110.2)天,肿瘤组房颤复发6例(20.0%),对照组复发17例(28.3%),两组复发率差异无统计学意义(P>0.05)。
- Kaplan-Meier生存分析显示是否罹患恶性肿瘤对射频消融术后房颤复发率无影响(P=0.383)。
- 多因素Cox回归分析校正混杂因素后,罹患恶性肿瘤与射频消融术后房颤复发仍无相关性(HR=0.508,95%CI 0.192~1.342,P=0.172)。
- 随访期间两组均未出现全因死亡。
临床怎么用
- 对于合并恶性肿瘤的房颤患者,射频消融治疗可考虑作为可行的节律控制策略。
局限性
- 本研究为单中心回顾性研究,样本量较小(共90例),随访时间有限,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the impact of cancer on the recurrence rate of atrial fibrillation (AF) after AF radiofrequency ablation and further evaluate the feasibility of radiofrequency ablation therapy in cancer patients with AF. Methods: This study was a single-center, retrospective study. Cancer patients with AF undergoing radiofrequency ablation for the first time in the First Affiliated Hospital of Dalian Medical University from May 30, 2008 to September 30, 2018 were included (cancer group). AF patients without cancer undergoing radiofrequency ablation for the first time during the same period served as non-cancer group. Clinical data including age, gender, past history, cancer and AF-related parameters, etc. were analyzed. Patients were followed up after radiofrequency ablation. The primary endpoints were AF recurrence or all-cause death. Kaplan-Meier survival analysis was used to analyze the effect of cancers on the recurrence after AF ablation. The multivariate cox regression analysis was further applied to correct for other confounding factors to analyze whether the impact of cancers on the recurrence of atrial fibrillation was statistically significant. Results: A total of 90 patients were enrolled, there were 30 patients in the cancer group (mean age (64.8±6.6) years, 16 (53.3%) males) and 60 patients in the non-cancer group (mean age (63.6±6.2) years, 32 (53.3%) males). Clinical data, such as age, gender, and cancer treatment, were similar between the two groups. During an average follow-up period of (328.7±110.2) days, there were 6 AF recurrences (recurrence rate 20.0%) in the cancer group, and 17 AF recurrences (recurrence rate 28.3%) in the control group. AF recurrence rate was similar between the two groups (P>0.05). During the follow-up period, there was no all-cause death in the two groups. Kaplan-Meier survival analysis showed that cancer was not related to AF recurrence after radiofrequency ablation (P = 0.383). After adjusting for other confounding factors, the multivariate Cox regression analysis showed that cancer was not an independent predictor of AF recurrence after radiofrequency ablation (HR=0.508, 95%CI: 0.192-1.342, P = 0.172). Conclusions: The combination of cancer has no impact on the recurrence of AF after radiofrequency ablation. For cancer patients with AF, radiofrequency ablation therapy can be considered as a feasible heart rhythm control treatment strategy. 目的: 分析罹患恶性肿瘤对心房颤动(房颤)射频消融术后房颤复发率的影响,探讨射频消融用于恶性肿瘤患者的可行性。 方法: 本研究为一项单中心的回顾性研究,选取2008年5月30日至2018年9月30日于大连医科大学附属第一医院首次行射频消融治疗的恶性肿瘤合并房颤患者,设置为肿瘤组。选取同时期既往无恶性肿瘤病史且首次行射频消融治疗的房颤患者设置为对照组。收集患者的临床资料,包括年龄、性别、既往史、肿瘤和房颤相关指标等。射频消融术后对患者进行随访,随访终点为房颤复发或全因死亡。采用Kaplan-Meier生存分析模型分析恶性肿瘤对射频消融术后房颤复发的影响。校正混杂因素后,进一步采用多因素Cox回归分析恶性肿瘤对房颤复发的影响。 结果: 共纳入90例患者,其中肿瘤组30例,年龄(64.8±6.6)岁,男性16例(53.3%)。对照组60例,年龄(63.6±6.2)岁,男性32例(53.3%)。2组患者的年龄、性别、肿瘤治疗情况等临床资料比较差异均无统计学意义。随访(328.7±110.3)d,肿瘤组房颤复发6例(复发率20.0%),对照组房颤复发17例(复发率28.3%),2组患者房颤复发率差异无统计学意义。随访期间内2组均未出现全因死亡。Kaplan-Meier生存分析结果显示,是否罹患恶性肿瘤对射频消融术后房颤复发率无影响(P=0.383)。多因素Cox回归分析提示,校正其他混杂因素后,罹患恶性肿瘤与射频消融术后房颤复发之间仍无相关性(HR=0.508,95%CI 0.192~1.342,P=0.172)。 结论: 罹患恶性肿瘤对射频消融术后房颤复发无影响。对于合并房颤的恶性肿瘤患者,射频消融治疗可视为一种可行的心脏节律控制治疗策略。.
引用
- Wang YS, Li DB, Chen C, et al. [Feasibility of radiofrequency ablation for cancer patients with atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 34404188. doi:10.3760/cma.j.cn112148-20200922-00758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。